Preclinical Studies of Amixicile, a Systemic Therapeutic Developed for Treatment of Clostridium difficile Infections That Also Shows Efficacy against Helicobacter pylori

Amixicile shows efficacy in the treatment of Clostridium difficile infections (CDI) in a mouse model, with no recurrence of CDI. Since amixicile selectively inhibits the action of a B vitamin (thiamine pyrophosphate) cofactor of pyruvate:ferredoxin oxidoreductase (PFOR), it may both escape mutation-...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hoffman, Paul S., Bruce, Alexandra M., Olekhnovich, Igor, Warren, Cirle A., Burgess, Stacey L., Hontecillas, Raquel, Viladomiu, Monica, Bassaganya-Riera, Josep, Guerrant, Richard L., Macdonald, Timothy L.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2014
Sujets:
Experimental Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4136022/
https://ncbi.nlm.nih.gov/pubmed/24890599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.03112-14
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires